To address this limitation, nanotherapies delivering a SHP‐1 inhibitor downstream of the CD47–SIRPα axis were developed and demonstrated the ability to reduce vascular inflammation without inducing anemia in large animal models [192]. This evidence concerns the gene CD47 and anemia.